Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Safinamide.

Ruggero G Fariello1

  • 1BioNeuroFar s.a.s, V. Della Vittoria 22 21016, Luino, Italy. ruggero@fariello.com

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|January 3, 2007
PubMed
Summary
This summary is machine-generated.

Safinamide, an anticonvulsant, shows promise in treating epilepsy by blocking sodium channels and inhibiting glutamate release. A pilot study indicated significant seizure reduction in refractory epilepsy patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synergistically Acting on Myostatin and Agrin Pathways Increases Neuromuscular Junction Stability and Endurance in Old Mice.

Aging and disease·2023
Same author

A new protein curbs the hypertrophic effect of myostatin inhibition, adding remarkable endurance to motor performance in mice.

PloS one·2020
Same author

Injection of a soluble fragment of neural agrin (NT-1654) considerably improves the muscle pathology caused by the disassembly of the neuromuscular junction.

PloS one·2014
Same author

Broad spectrum and prolonged efficacy of dimiracetam in models of neuropathic pain.

Neuropharmacology·2014
Same author

A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's disease.

British journal of clinical pharmacology·2012
Same author

Identification and quantification of dolichol and dolichoic acid in neuromelanin from substantia nigra of the human brain.

Journal of lipid research·2007
Same journal

Neurological complications of current and emerging CAR-T cell therapies.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Hemodynamics Beyond Ischemic Zone Underlies Early Neurological Deterioration in Minor Stroke with Large Vessel Occlusion.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Long-term efficacy of subthalamic nucleus deep brain stimulation in focal motor seizures and implications for candidate selection.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Brain interstitial fluid pharmacokinetics and therapeutic effect of a BBB penetrating amyloid beta antibody measured by microdialysis.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Advances in the management of pediatric low-grade glioma.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Therapeutic hypothermia protects the ischemic penumbra via Xkr8.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology
  • Epileptology

Background:

  • Safinamide (SAF) is an anticonvulsant agent initially synthesized for its broad spectrum of action and safety.
  • Its mechanism involves voltage-sensitive sodium channel blockade, calcium channel modulation, and glutamate release inhibition.

Purpose of the Study:

  • To evaluate the efficacy and safety of safinamide in patients with refractory epilepsy.
  • To explore the neuroprotective and neurorescuing properties of safinamide.

Main Methods:

  • A pilot phase II study involving 38 refractory epilepsy patients.
  • Escalating doses of safinamide up to 300 mg once daily over 12 weeks.
  • Assessment of seizure reduction compared to baseline.

Related Experiment Videos

Main Results:

  • 41% of patients achieved a 50% or greater reduction in seizure frequency.
  • Safinamide demonstrated a good safety margin and was suitable for once-daily oral administration.
  • In vitro and in vivo studies indicated neurorescuing and neuroprotectant effects.

Conclusions:

  • Safinamide shows significant potential as an add-on therapy for refractory epilepsy.
  • Its multifaceted pharmacological profile supports its neuroprotective capabilities.
  • Further development is ongoing, including Phase III trials for Parkinson's disease.